New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
09:16 EDTSPPI, ARNA, GTAT, CASI, BDSI, DISH, ENDP, NQOn The Fly: Pre-market Movers
HIGHER: DISH (DISH), up 2.4% following positive mention in this weekend's Barron's, contending the shares could climb 20%... BioDelivery Sciences (BDSI), up 15% after announcing results from its Endo buprenorphine trial with an Endo (ENDP) division... CASI Pharmaceuticals (CASI), up 3.7% after confirming that it received FDA orphan drug designation for a drug... Spectrum (SPPI), up 3% after being granted accelerated approval for Beleodaq from FDA. LOWER: GT Advanced (GTAT), down 10% after downgraded at UBS and Cannaccord... NQ Mobile (NQ), down 3.5% after Muddy Waters says the company has likely already decided to fire PwC... Arena Pharmaceuticals (ARNA), down 3% after Chairman, President and CEO Jack Lief sold 223,525 shares of the company's common stock pursuant to a Rule 10b5-1 trading plan on July 1, according to a regulatory filing from late Thursday.
News For DISH;GTAT;NQ;BDSI;ARNA;ENDP;CASI;SPPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 30, 2015
07:04 EDTSPPISpectrum presents new data on Evomela
Spectrum Pharmaceuticals announced results of a clinical study of the stability of Captisol-enabled Melphalan versus the currently marketed, propylene glycol-containing melphalan formulation entitled, Solution Stability of Captisol-enabled Melphalan vs Marketed Melphalan Products. These results were presented in an oral presentation at the annual American Pharmacists Association Annual Meeting & Exposition in San Diego, California.“The improved stability of EVOMELA may potentially ensure that cancer patients receive the full, intended therapeutic dose of intravenous melphalan, by increasing the use time and infusion time, and simplifying clinical administration logistics,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals. “EVOMELA is a new injectable formulation of melphalan that incorporates the Captisol brand of modified β-cyclodextrin improving the solubility and stability of melphalan. It also uses a standard aqueous diluent for reconstitution, instead of propylene glycol, which is associated with toxicities including renal dysfunction and arrhythmias. We look forward to launching EVOMELA with our existing sales force later this year and providing this new treatment option to cancer patients.”
06:39 EDTBDSIBioDelivery primary endpoint in Clonidine study not statistically significant
BioDelivery Sciences announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance, although certain secondary endpoints showed statistically significant improvement over placebo. In addition, a strong safety profile for the product was observed. The results of this trial provide data that will allow the company to better refine the protocol criteria to capture a more "enriched" patient population and target site selection. Secondary efficacy endpoints statistically significant.
March 27, 2015
09:37 EDTBDSIActive equity options trading on open
Subscribe for More Information
06:14 EDTDISHAT&T betting on slow decline in traditional cable packages, WSJ says
AT&T (T) knew that demand for cable bundles had likely peaked when it bought DirecTV (DTV), but the company believes the decline in traditional cable businesses will be slower than anticipated, allowing it to fund upgrades to its broadband network, reports the Wall Street Journal, citing statements by Chief Strategy Officer John Stankey. "The world is going to be broadband... and that is where we want to be," said Stankey. The Journal notes that Apple (AAPL), Time Warner's (TWC) HBO, and Dish (DISH) have launched or plan to launch web-TV packages and services. Reference Link
March 26, 2015
13:46 EDTBDSIBioDelivery Sciences volatility elevated
BioDelivery Sciences April call option implied volatility is at 126, May is at 101, June is at 82; compared to its 26-week average of 78 according to Track Data, suggesting large near term price movement.
07:30 EDTENDPDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 25, 2015
12:58 EDTENDPPershing Square raises stake in Valeant, says will discuss acquisitions
Subscribe for More Information
10:30 EDTDISHDISH Chairman Ergen says early Sling TV results 'encouraging'
Charlie Ergen is speaking on CNBC
10:29 EDTDISHDISH Chairman Ergen says Comcast, TWC merger should be blocked
Subscribe for More Information
07:12 EDTENDPAmerican Academy of Orthopedic Surgeons to hold annual meeting
Subscribe for More Information
07:01 EDTCASICASI Pharmaceuticals initiates Phase 2 trial with ENMD-2076
Subscribe for More Information
March 24, 2015
10:52 EDTNQChinaRock Capital reports 5.75% stake in NQ Mobile
Subscribe for More Information
March 20, 2015
16:33 EDTENDPStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information
15:31 EDTENDPEndo management to meet with Sterne Agee
Subscribe for More Information
15:16 EDTBDSIBioDelivery Sciences April volatility elevated
Subscribe for More Information
10:00 EDTDISHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:49 EDTDISHDISH initiated with an Underperform at BMO Capital
Subscribe for More Information
06:36 EDTDISHWeb TV companies ask internet providers for special treatment, WSJ says
Subscribe for More Information
March 19, 2015
09:20 EDTNQOn The Fly: Pre-market Movers
Subscribe for More Information
09:07 EDTNQNQ Mobile appoints Chun Ding as independent director of board
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use